Evidence map›Paper›PMID 40183433›Full record

ArticleNeurodegenerative disease management

Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.

JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurodegenerative disease management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

JingSi JiangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
XiaoGang LiDepartment of Neurology, Peking University Third Hospital, Beijing, China.
YuXin MiDaxing Research Institute, University of Science and Technology Beijing, Beijing, China.
YiYing WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
YanXi HengInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
ZhiWen LiInstitute of Reproductive and Child Health/National Health Commission Key Laboratory of Reproductive Health, Peking University School of Public Health, Beijing, China.
Min DengInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS). PATIENTS &

methodsPropensity score matching was used to balance baseline variables between the riluzole group (

resultsRiluzole did not significantly improve survival (

conclusionsRiluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.

Indexed as

Amyotrophic Lateral SclerosisNeuroprotective AgentsRiluzoleAdultAgedChinaCohort StudiesEast Asian PeopleFemaleHumansKaplan-Meier EstimateMaleMiddle AgedTreatment OutcomeNeuroprotective AgentsRiluzoleamyotrophic lateral sclerosisamyotrophic lateral sclerosis*/drug therapyreal-worldRiluzolesurvival

Identifiers

PMID40183433
PMCPMC12118432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.